TrialBMC neurology2021

Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.

S Neumann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.